DeepMed Research

National Eye Institute

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private, Subsidiary

Established: 1968-01-01

Employees: 101

Market Cap: -

Website: http://www.nei.nih.gov

Clinical Trials

Detection of Neutralizing Antibodies in Patients Treated With Bevacizumab or Ranibizumab

Completed

Conditions: Macular Degeneration

First Posted Date: 2008-01-31

Last Posted Date: 2017-07-02

Lead Sponsor: National Eye Institute (NEI)

Target Recruit Count: 30

Registration Number: NCT00605943

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Age-Related Eye Disease Study (AREDS) Follow-Up

Active, not recruiting

Conditions: Cataract
Age-Related Macular Degeneration

First Posted Date: 2008-01-16

Last Posted Date: 2025-05-21

Lead Sponsor: National Eye Institute (NEI)

Target Recruit Count: 110

Registration Number: NCT00594672

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

30-Day Trial of Oral Valtrex or Valtrex Plus Aspirin on Shedding of HSV DNA in Tears and Saliva of Volunteers

Phase 1

Conditions: Herpes Simplex

Interventions: Drug: placebo
Drug: valacyclovir hydrochloride
Drug: valacyclovir plus aspirin

First Posted Date: 2008-01-07

Last Posted Date: 2008-01-07

Lead Sponsor: National Eye Institute (NEI)

Target Recruit Count: 60

Registration Number: NCT00587496

Locations: 🇺🇸
LSU Eye Center, New Orleans, Louisiana, United States
🇺🇸
Children's Hospital, New Orleans, Louisiana, United States

Visual Motor Coordination

Terminated

Conditions: Neurodegenerative Diseases
Healthy Volunteer

First Posted Date: 2007-12-05

Last Posted Date: 2024-04-12

Lead Sponsor: National Eye Institute (NEI)

Target Recruit Count: 34

Registration Number: NCT00568243

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Potential Research Participants for Future Studies of Inherited Eye Diseases

Completed

Conditions: Strabismus
Cataract
Glaucoma
Retinitis Pigmentosa
Macular Degeneration

First Posted Date: 2007-11-16

Last Posted Date: 2017-07-02

Lead Sponsor: National Eye Institute (NEI)

Target Recruit Count: 400

Registration Number: NCT00559234

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Human Samples and Data Repository

Terminated

Conditions: Uveitis
Scleritis

First Posted Date: 2007-10-04

Last Posted Date: 2022-08-26

Lead Sponsor: National Eye Institute (NEI)

Target Recruit Count: 1862

Registration Number: NCT00539370

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Dry Eye in Women With Turner Syndrome and Women With Premature Ovarian Failure

Completed

Conditions: Perimenopause
Ovarian Failure, Premature
Menopause
Sex Chromosome Aberrations
Turner Syndrome

First Posted Date: 2007-05-10

Last Posted Date: 2018-02-14

Lead Sponsor: National Eye Institute (NEI)

Target Recruit Count: 72

Registration Number: NCT00471731

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

TAC-PF, Avastin® in Combination With Photodynamic Therapy to Treat Age Related Macular Degeneration

Phase 2

Terminated

Conditions: Age-Related Macular Degeneration

First Posted Date: 2007-04-23

Last Posted Date: 2010-03-24

Lead Sponsor: National Eye Institute (NEI)

Target Recruit Count: 100

Registration Number: NCT00464347

Locations: 🇺🇸
Duke University Eye Center, Durham, North Carolina, United States
🇺🇸
VitroRetinal Surgery, Minneapolis, Minnesota, United States
🇺🇸
Palmetto Retina Center, Columbia, South Carolina, United States

and more 8 locations

Injected Ranibizumab to Treat Macular Telangiectasia With New Blood Vessel Formation

Phase 1

Completed

Conditions: Telangiectasia

First Posted Date: 2007-04-05

Last Posted Date: 2017-07-02

Lead Sponsor: National Eye Institute (NEI)

Target Recruit Count: 5

Registration Number: NCT00457067

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Injected Ranibizumab to Treat Macular Telangiectasia Without New Blood Vessel Formation

Phase 1

Completed

Conditions: Telangiectasia

First Posted Date: 2007-04-05

Last Posted Date: 2017-07-02

Lead Sponsor: National Eye Institute (NEI)

Target Recruit Count: 5

Registration Number: NCT00457145

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy